Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis utilizing the next-generation fully retrievable and repositionable valve system: mid-term results from a prospective multicentre registry
Authors:
- Janusz KochmanJKJanusz Kochman
- Karol ZbrońskiKZKarol Zbroński
- Łukasz KołtowskiŁKŁukasz Kołtowski
- Radosław ParmaRPRadosław Parma
- Andrzej OchałaAOAndrzej Ochała
- Zenon HuczekZHZenon Huczek
- Radosław WilimskiRWRadosław Wilimski
- Maciej DąbrowskiMDMaciej Dąbrowski
- Adam WitkowskiAWAdam Witkowski
- Piotr ScisłoPSPiotr Scisło
- Marek GrygierMGMarek Grygier
Open Access
- 2 September 2019
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 109 (5) , 570-580
Abstract
Background The aim of this study was to evaluate the outcomes of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BiAV) stenosis using a mechanically expanded Lotus™ device. The prior experience with first-generation devices showed disappointing results mainly due to increased prevalence of aortic regurgitation (AR) that exceeded those observed in tricuspid stenosis. Methods and results We collected baseline, in-hospital, 30-day and 2-year follow-up data from a prospective, multicentre registry of patients with BiAV undergoing TAVI using Lotus™ valve. Safety and efficacy endpoints were assessed according to VARC-2 criteria. The study group comprised 24 patients. The mean age was 73.5 years and the mean EuroSCORE 2 was 4.35 ± 2.56%. MDCT analysis revealed Type 1 BiAV in 75% of patients. The mean gradient decreased from 60.1 ± 18.3 to 15 ± 6.4 mm Hg, the AVA increased from 0.6 ± 0.19 to 1.7 ± 0.21 cm2. One in-hospital death was observed secondary to aortic perforation. There was no severe AR and the rate of moderate AR equalled 9% at 30 days (n = 2). Device success was achieved in 83% and the 30-day safety endpoint was 17%. In the 2-year follow-up, the overall mortality was 12.5% and the 2-year composite clinical efficacy endpoint was met in 25% of the patients (n = 6) Conclusions The TAVI in selected BiAV patients using the Lotus™ is feasible and characterized by encouraging valve performance and mid-term clinical outcomes. Graphic abstractKeywords
This publication has 33 references indexed in Scilit:
- Transcatheter Aortic Valve Implantation With or Without Preimplantation Balloon Aortic Valvuloplasty: A Systematic Review and Meta‐AnalysisJournal of the American Heart Association, 2016
- 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve ReplacementJACC, 2015
- Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve DiseaseJACC, 2014
- Transcatheter Aortic Valve Replacement for Severe Symptomatic Aortic Stenosis Using a Repositionable Valve SystemJACC, 2014
- 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive SummaryCirculation, 2014
- Transcatheter Aortic Valve Implantation for Patients With Severe Bicuspid Aortic Valve StenosisCirculation: Cardiovascular Interventions, 2013
- Predictors of permanent pacemaker implantation after Medtronic CoreValve bioprosthesis implantationEP Europace, 2012
- Transcatheter aortic valve implantationCatheterization and Cardiovascular Interventions, 2011
- Diagnostic Value of Cardiac CT in the Evaluation of Bicuspid Aortic Stenosis: Comparison With Echocardiography and Operative FindingsAmerican Journal of Roentgenology, 2010
- Bicuspid Aortic Valve DiseaseJACC, 2010